The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

Tamiem Adam; Therese M. Becker; Wei Chua; Victoria Bray; Tara L. Roberts

doi:10.3390/cancers13020277

The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

Tamiem Adam, Therese M. Becker, Wei Chua, Victoria Bray, Tara L. Roberts

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

Original language	English
Article number	277
Pages (from-to)	1-20
Number of pages	20
Journal	Cancers
Volume	13
Issue number	2
DOIs	https://doi.org/10.3390/cancers13020277
Publication status	Published - 2 Jan 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors.

Open Access - Access Right Statement

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Keywords

biochemical markers
cancer
immunotherapy
melanoma
renal cell carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13020277

Cite this

@article{309bc5bf2c104d38ac5c354b3822b74a,

title = "The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack",

abstract = "Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.",

keywords = "biochemical markers, cancer, immunotherapy, melanoma, renal cell carcinoma",

author = "Tamiem Adam and Becker, {Therese M.} and Wei Chua and Victoria Bray and Roberts, {Tara L.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors.",

year = "2021",

month = jan,

day = "2",

doi = "10.3390/cancers13020277",

language = "English",

volume = "13",

pages = "1--20",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

AU - Adam, Tamiem

AU - Becker, Therese M.

AU - Chua, Wei

AU - Bray, Victoria

AU - Roberts, Tara L.

PY - 2021/1/2

Y1 - 2021/1/2

N2 - Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

AB - Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

KW - biochemical markers

KW - cancer

KW - immunotherapy

KW - melanoma

KW - renal cell carcinoma

UR - http://hdl.handle.net/1959.7/uws:58573

U2 - 10.3390/cancers13020277

DO - 10.3390/cancers13020277

M3 - Article

SN - 2072-6694

VL - 13

SP - 1

EP - 20

JO - Cancers

JF - Cancers

IS - 2

M1 - 277

ER -

The multiple potential biomarkers for predicting immunotherapy response : finding the needle in the haystack

Abstract

Bibliographical note

Open Access - Access Right Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this